Emergent BioSolutions Inc. (NYSE:EBS) finished Friday with a subtraction of -$0.04 to close at $11.81, a downside of -0.34 percent. An average of 808,980 shares of common stock have been traded in the last five days. There was a gain of $0.77 in the past week, and it reached a new high 6 times over the past 12 months. The last 20 days have seen an average of 1,106,360 shares traded, while the 50-day average volume stands at 1,022,360.
EBS stock has decreased by -3.98% in the last month. The company shares reached their 1-month lowest point of $10.61 on 12/22/22. With the stock rallying to its 52-week high on 01/14/22, shares of the company touched a low of $10.61 and a high of $52.28 in 52 weeks. It has reached a new high 5 times so far this year and lost -72.83% or -$31.66 in price. In spite of this, the price is down -77.41% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
EBS stock investors should be aware that Emergent BioSolutions Inc. (EBS) stock had its last reported insider trading activity 36 days ago on Nov 25. In this transaction, the insider spent $22,829. Director, Zoon Kathryn C, disposed of 1,173 shares at a price of $31.52 on Jun 09. The insider now owns more than $36,973 worth of shares. Prior to that, Director Zoon Kathryn C went on to Sale 1,996 shares at $35.53 each on May 24. An amount of $70,918 was transacted.
Emergent BioSolutions Inc. (EBS) has a trailing price-to-earnings (P/E) ratio of 14.40. The stock’s beta is 0.92. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.39, the price-to-book (PB) ratio at 0.41, and the price-to-cash flow ratio at 9.36.
The quick ratio of Emergent BioSolutions Inc. for the three months ended September 29 was 2.10, and the current ratio was 4.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.71 and a total debt to equity ratio of 0.73 for the quarter ending September 29. Its gross profit as reported stood at $1.04 billion compared to revenue of $1.79 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Emergent BioSolutions Inc.’s return on assets was 1.90%.
For the three-month period that ended September 29, Emergent BioSolutions Inc. had $1.03 billion in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$75.7 million in the quarter, while revenues of -$56.4 million were grew 56.8%. The analyst consensus anticipated Emergent BioSolutions Inc.’s latest quarter earnings to come in at -$0.06 per share, but it turned out to be -$1.27, a -2,016.70% surprise. For the quarter, EBITDA amounted to -$8.6 million. Shareholders own equity worth $49.89 million.
From a technical analysis perspective, let’s take a brief look at Emergent BioSolutions Inc. (EBS) price momentum. RSI 9-day as of the close on 30 December was 52.89%, suggesting the stock is Neutral, with historical volatility in this time frame at 42.27%.
As of today, EBS’s price is $11.36 +6.97% or $0.77 from its 5-day moving average. However, the stock’s current price level is -36.33% below the SMA50 and -69.83% below the SMA200.
The stochastic %K and %D were 42.20% and 30.71%, respectively, and the average true range (ATR) was 0.65. With the 14-day stochastic at 51.50% and the average true range at 0.72, the RSI (14) stands at 44.42%. The stock has reached 0.27 on the 9-day MACD Oscillator while the 14-day reading was at 0.15.
The Benchmark Company downgraded Emergent BioSolutions Inc. (NYSE: EBS) to a a Hold rating in its most recent analyst report. Previously, the stock was rated as a Buy. The consensus rating for Emergent BioSolutions Inc. (EBS) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell EBS, while 4 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 2 others rate it as a “buy”.
What is EBS’s price target for the next 12 months?
Analysts predict a range of price targets between $23.00 and $55.00, with a median target of $25.00. Taking a look at these predictions, the average price target given by analysts for Emergent BioSolutions Inc. (EBS) stock is $30.40.